Royalty Pharma (RPRX) Return on Sales (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Return on Sales data on file, last reported at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales changed 0.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
• Return on Sales grew to 0.01% in Q1 2026, from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q3 2024 to a low of 0.01% in Q4 2022.
• A 5-year average of 0.01% and a median of 0.01% in 2025 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales fell 1 bps in 2022 and grew 2 bps in 2023, its largest moves.
• Tracing RPRX's Return on Sales over 5 years: stood at 0.01% in 2022, then soared by 212 bps to 0.01% in 2023, then plunged by 53 bps to 0.01% in 2024, then grew by 2 bps to 0.01% in 2025, then gained by 30 bps to 0.01% in 2026.
• Business Quant data shows RPRX's Return on Sales at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.